Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.39 |
| ▸ | HTR1D | P28221 | 3/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216180 | 0.90 | KRAS (0.54) | KRASCYP3A4CYP1A2CYP2C19SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3614572 | 0.89 | KRAS (0.53) | KRASCYP3A4CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL3224445 | 0.86 | KRAS (0.57) | KRASCYP3A4CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL13493974 | 0.85 | CYP1A2 (0.44) | KRASCYP3A4CYP1A2CYP2C19ADRA2A | |
| SCHEMBL3235519 | 0.82 | KRAS (0.45) | KRASCYP3A4CYP1A2CYP2C19SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3582811 | 0.81 | SMN1; SMN2 (0.47) | KRASCYP3A4CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL13496702 | 0.81 | CYP1A2 (0.43) | KRASCYP3A4CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL3234804 | 0.81 | CYP1A2 (0.43) | KRASCYP3A4CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL3260476 | 0.80 | CYP1A2 (0.45) | KRASCYP3A4CYP1A2CYP2C19ADRA2A | |
| Hydrochloric Acid SCHEMBL3622627 | 0.79 | SMN1; SMN2 (0.43) | KRASCYP3A4CYP1A2CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010012397-A1 | N-(INDOL-3-YLALKYL)(HETERO)ARYLAMIDE DERIVATIVES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | BAYER SCHERING PHARMA AG (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | BAYER SCHERING PHARMA AG (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | BAYER SCHERING PHARMA AG (DE) | 2010-02-04 | — | — | US | disclosed |
| EP-2149551-A1 | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | disclosed |
| EP-2149551-A1 | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | PTGER2, PTGER1, PTGDR2 | KRAS 4229/4885CYP3A4 492/4885CYP1A2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.